ERD

Reporting of adverse effects of intradermal vs. intranodal administration of tolDC to investigators, data safety monitor...

Project: RESTORE

Updated at: 31-05-2024

Show more information

Project acronym RESTORE

Report on the overall safety and tolerability of tolDC therapy

Project: RESTORE

Updated at: 06-05-2024

Show more information

Project acronym RESTORE

Dissemination materials (2)

Project: RESTORE

Updated at: 06-05-2024

Show more information

Project acronym RESTORE

Dissemination materials (3)

Project: RESTORE

Updated at: 06-05-2024

Show more information

Project acronym RESTORE

Report on clinical trial design and voluntary harmonization procedure

Project: RESTORE

Updated at: 06-05-2024

Show more information

Project acronym RESTORE

Report on overall study monitoring

Project: RESTORE

Updated at: 06-05-2024

Show more information

Project acronym RESTORE

Stakeholder committee evaluation report (3)

Project: RESTORE

Updated at: 06-05-2024

Show more information

Project acronym RESTORE

Stakeholder committee evaluation report (1)

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Training for all personnel involved in the clinical trial

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Data Management Plan

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Dissemination materials

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Certificates of clinical training

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Plans for dissemination and exploitation of the results

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clin...

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Guidelines for analysis of low-frequency antigen-specific T cell results: Dye-based proliferation assay vs 3H-thymidine ...

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonized study protocol for two phase I clin...

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Ways Forward for Tolerance-Inducing Cellular Therapies- an AFACTT Perspective

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Beyond the Magic Bullet: Current Progress of Therapeutic Vaccination in Multiple Sclerosis

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Documentation of adverse effects in the second cohort receiving the intermediate dose of peptide-loaded tolDC

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Project website, including internal section for partners

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

MAP7 and MUCL1 Are Biomarkers of Vitamin D3-Induced Tolerogenic Dendritic Cells in Multiple Sclerosis Patients

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Documentation of adverse effects in the third cohort receiving the highest dose of peptide-loaded tolDC

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Stakeholder committee evaluation report (2)

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Transfection of Vitamin D3-Induced Tolerogenic Dendritic Cells for the Silencing of Potential Tolerogenic Genes. Identif...

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Made to Measure: Patient-Tailored Treatment of Multiple Sclerosis Using Cell-Based Therapies.

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4+ Cells Towards a Functional ...

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Safety and immunological proof-of-concept following treatment with tolerance-inducing cell products in patients with aut...

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosi...

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Documentation of adverse effects in the first cohort receiving the lowest dose of tolDC

Project: RESTORE

Updated at: 31-10-2023

Show more information

Project acronym RESTORE

Resources

Selected filters:

Reporting of adverse effects of intradermal vs. intranodal administration of tolDC to investigators, data safety monitor...

Report on the overall safety and tolerability of tolDC therapy

Dissemination materials (2)

Dissemination materials (3)

Report on clinical trial design and voluntary harmonization procedure

Report on overall study monitoring

Stakeholder committee evaluation report (3)

Stakeholder committee evaluation report (1)

Training for all personnel involved in the clinical trial

Data Management Plan

Dissemination materials

Certificates of clinical training

Plans for dissemination and exploitation of the results

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clin...

Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy

Guidelines for analysis of low-frequency antigen-specific T cell results: Dye-based proliferation assay vs 3H-thymidine ...

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonized study protocol for two phase I clin...

Ways Forward for Tolerance-Inducing Cellular Therapies- an AFACTT Perspective

Beyond the Magic Bullet: Current Progress of Therapeutic Vaccination in Multiple Sclerosis

Documentation of adverse effects in the second cohort receiving the intermediate dose of peptide-loaded tolDC

Project website, including internal section for partners

MAP7 and MUCL1 Are Biomarkers of Vitamin D3-Induced Tolerogenic Dendritic Cells in Multiple Sclerosis Patients

Documentation of adverse effects in the third cohort receiving the highest dose of peptide-loaded tolDC

Stakeholder committee evaluation report (2)

Transfection of Vitamin D3-Induced Tolerogenic Dendritic Cells for the Silencing of Potential Tolerogenic Genes. Identif...

Made to Measure: Patient-Tailored Treatment of Multiple Sclerosis Using Cell-Based Therapies.

Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4+ Cells Towards a Functional ...

Safety and immunological proof-of-concept following treatment with tolerance-inducing cell products in patients with aut...

Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosi...

Documentation of adverse effects in the first cohort receiving the lowest dose of tolDC